CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy. Academic Article uri icon

Overview

abstract

  • PD-L1/2 expression in solid tumors inhibits chimeric antigen receptor (CAR) T-cell efficacy. A PD-1 dominant negative receptor expressed in CAR T cells provides cell-intrinsic checkpoint blockade and augments antitumor efficacy. A combinatorial immunotherapeutic strategy of combining CAR T cells with checkpoint blockade is a promising treatment approach for solid tumors.

publication date

  • December 23, 2016

Identity

PubMed Central ID

  • PMC5353939

Scopus Document Identifier

  • 85011825145

Digital Object Identifier (DOI)

  • 10.1038/nrclinonc.2015.209

PubMed ID

  • 28344886

Additional Document Info

volume

  • 6

issue

  • 2